- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Neoadjuvant Chemotherapy for Advanced Ovarian Cancer ; volume:28 ; number:01 ; year:2007 ; pages:4-5
Indian journal of medical & paediatric oncology ; 28, Heft 01 (2007), 4-5
- Contributor
-
Hariprasad, Roopa
Kumar, L.
Kapoor, Col.A
- DOI
-
10.1055/s-0041-1733195
- URN
-
urn:nbn:de:101:1-2022051210105291137634
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hariprasad, Roopa
- Kumar, L.
- Kapoor, Col.A
Other Objects (12)
Adjuvant vs Neoadjuvant Chemotherapy In Advanced Ovarian Cancer
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Study
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
Neoadjuvant Chemotherapy (NACT) in Advanced Epithelial Ovarian Cancer: International Data and TMH Experience
Neo-adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Prospective, Randomized Study
Chemotherapy for Advanced Epithelial Ovarian Cancer
Does neoadjuvant chemotherapy reduce surgical complexity in patients with advanced-stage epithelial ovarian cancer?
Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
Adjuvant vs Neoadjuvant Chemotherapy In Advanced Ovarian Cancer
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Study
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
Neoadjuvant Chemotherapy (NACT) in Advanced Epithelial Ovarian Cancer: International Data and TMH Experience
Neo-adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Prospective, Randomized Study
Chemotherapy for Advanced Epithelial Ovarian Cancer
Does neoadjuvant chemotherapy reduce surgical complexity in patients with advanced-stage epithelial ovarian cancer?
Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
Adjuvant vs Neoadjuvant Chemotherapy In Advanced Ovarian Cancer
Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Retrospective Study
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
Neoadjuvant Chemotherapy (NACT) in Advanced Epithelial Ovarian Cancer: International Data and TMH Experience
Neo-adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Prospective, Randomized Study
Chemotherapy for Advanced Epithelial Ovarian Cancer
Does neoadjuvant chemotherapy reduce surgical complexity in patients with advanced-stage epithelial ovarian cancer?
Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer